冠状病毒病-2019(COVID-19)是由SARS-CoV-2病毒引起的极具传染性的疾病,已被世界卫生组织(WHO)宣布为大流行。目前没有特殊的治疗方法,然而,雾化肝素已被提供作为一种可行的治疗方法。这项系统评价的目的是评估雾化肝素在有呼吸道症状的COVID-19患者中的疗效。
■通过对PubMed的系统搜索确定了相关研究,Medline,Embase,Cochrane图书馆和WebofScience,和Scopus数据库。搜索词包括“雾化肝素,\“\”COVID-19,\“和\”SARS-CoV-2。“包括评估雾化肝素在有呼吸道症状的COVID-19患者中使用的研究。其余的研究以及未以英文发表的研究都被排除在外。系统评价在PROSPERO-CRD42023413927注册。
■本系统综述中包括了五项研究。病例报告,案例系列,观察性研究,随机对照试验(RCT)包括这些研究。患者样本量范围从2到98。这些研究评估了雾化肝素对疾病严重程度不同的COVID-19患者的疗效。评估的结果包括死亡率,住院时间,氧气需求,和实验室参数。
■根据本系统综述中的临床研究,雾化肝素可能有助于COVID-19的治疗。氧饱和度更高,炎症指标较低,这些患者的住院时间较短。然而,这些研究有局限性,包括不一致的样本量,不同剂量的雾化肝素,没有对照组。雾化肝素在COVID-19患者中的应用需要进一步研究,以确定其安全性和有效性。
■GuptaB,AhluwaliaP,GuptaN,GuptaA.雾化肝素在有呼吸道症状的COVID-19患者临床结局中的作用:系统评价。印度J暴击护理中心2023年;27(8):572-579。
Coronavirus disease-2019 (COVID-19) is an extremely contagious illness caused by the SARS-CoV-2 virus and has been declared a pandemic by the World Health Organization (WHO). There are currently no particular treatments, however, nebulized heparin has been offered as a viable therapy. The purpose of this systematic
review is to assess the efficacy of nebulized heparin in COVID-19 patients with respiratory symptoms.
UNASSIGNED: Relevant studies were identified through a systematic search of the PubMed, Medline, Embase, Cochrane Library and Web of Science, and Scopus databases. The search terms included \"nebulized heparin,\" \"COVID-19,\" and \"SARS-CoV-2.\" Studies that evaluated the use of nebulized heparin in COVID-19 patients with respiratory symptoms were included. The rest of the studies along with those that were not published in English were excluded. The systematic
review was registered under PROSPERO-CRD42023413927.
UNASSIGNED: Five studies have been included in this systematic
review. Case reports, case series, observational studies, and randomized controlled trial (RCT) comprised the studies. The patient sample sizes ranged from 2 to 98. The studies assessed the efficacy of nebulized heparin in COVID-19 patients with variable disease severity. The evaluated outcomes included mortality, hospital stay duration, oxygen requirements, and laboratory parameters.
UNASSIGNED: Based on the clinical studies included in this systematic
review, nebulized heparin may be useful in the management of COVID-19. Oxygen saturation was greater, inflammatory indicators were lower, and hospital stays were shorter in these patients. However, the studies had limitations, including inconsistent sample sizes, varying dosages of nebulized heparin, and no control groups. Nebulized heparin in patients with COVID-19 needs to be studied further to determine its safety and effectiveness.
UNASSIGNED: Gupta B, Ahluwalia P, Gupta N, Gupta A. Role of Nebulized Heparin in Clinical Outcome of COVID-19 Patients with Respiratory Symptoms: A Systematic
Review. Indian J Crit Care Med 2023;27(8):572-579.